IP Library Granted Patent US 11,273,202
Granted Patent B2
US 11,273,202 · App. 13/239,493 · Granted Mar 15, 2022

Formulations for bovine granulocyte colony stimulating factor and variants thereof

Inventors: Alan Voskamp Klotz (Indianapolis, IN); Catherine Ngan Kha (Raleigh, NC); Juan Davagnino (Durham, NC)
Assignee: ELANCO US INC.
A61K38/193C07K14/535
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,273,202
App. No.
13/239,493
Granted
Mar 15, 2022
Kind
B2
Abstract

This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.

Claims (19)

1. A stable aqueous formulation comprising

(a) a bovine granulocyte colony stimulating factor (bG-CSF) polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 comprising a non-naturally encoded amino acid substituted at position 133 of SEQ ID NO: 1 or the corresponding amino acid in SEQ ID NO: 2;

wherein the non-naturally encoded amino acid is para-acetylphenylalanine;

wherein said para-acetylphenylalanine is bonded to a water soluble polymer being a poly(ethylene) glycol moiety having a molecular weight of about 20 kDa;

(b) a citrate buffer;

(c) arginine, and optionally a counter ion for arginine;

(d) wherein said formulation contains less than 0.0033% of a surfactant; and

(e) wherein pH of the formulation ranges from 5.7 to 6.6.

2. The formulation of claim 1 wherein said surfactant is a polyoxyethylene derivative of sorbitan monolaurate.

3. The formulation of claim 2 wherein said surfactant is a polyoxyethylene (20) sorbitan monolaurate.

4. The formulation of claim 1 wherein the counter ion for arginine is chloride or sulfate.

5. The formulation of claim 1 optionally including one or more other therapeutic ingredients.

6. A lyophilisate or powder of the formulation of claim 1 .

7. A process for preparing the formulation of claim 1 comprising forming a stable aqueous solution comprising said bG-CSF polypeptide, a citrate buffer, arginine, and optionally a counter ion for arginine.

8. The formulation of claim 1 wherein said citrate buffer has a molarity of about 30 mM.

9. The formulation of claim 1 wherein said arginine has a molarity of about 250 mM.

10. The formulation of claim 8 wherein said arginine has a molarity of about 250 mM.

11. The formulation of claim 1 wherein the pH ranges from 6.0-6.3.

12. The formulation of claim 1 wherein the pH is 6.0±0.1.

Assignments (7)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON AUGUST 3, 2020, AT REEL/FRAME 053388/0967 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0021 →
SECURITY INTEREST Recorded Aug 3, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 053388/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: ELI LILLY AND COMPANY
To: ELANCO US INC.
Reel/Frame 044701/0234 →
RELEASE OF SECURITY INTEREST Recorded Mar 17, 2016
From: PACIFIC WESTERN BANK (AS SUCCESSOR IN INTEREST BY MERGER TO SQUARE 1 BANK)
To: KBI BIOPHARMA, INC.
Reel/Frame 038019/0267 →
SECURITY INTEREST Recorded Jul 13, 2015
From: KBI BIOPHARMA, INC.
To: SQUARE 1 BANK
Reel/Frame 036071/0636 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2011
From: DAVAGNINO, JUAN; KHA, CATHERINE NGAN
To: KBI BIOPHARMA, INC.
Reel/Frame 027434/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2011
From: KLOTZ, ALAN VOSKAMP; KBI BIOPHARMA, INC.
To: ELI LILLY AND COMPANY
Reel/Frame 027434/0176 →